Unassociated Document
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported)
May
19, 2009
DIGIRAD
CORPORATION
(Exact
name of registrant as specified in its charter)
Delaware
|
|
000-50789
|
|
33-0145723
|
(State
or other jurisdiction of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification
No.)
|
13950
Stowe Drive
Poway,
California 92064
(Address
of principal executive offices, including zip code)
(858)
726-1600
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
5.02. Departure of Directors or Principal Officers; Election of Directors;
Appointment of Principal Officers.
On May
19, 2009, Digirad Corporation, or the Company, appointed Steve Mendell and Lloyd
H. Malchow to the Company’s board of directors, or the Board, each to serve
until his successor is duly appointed and qualified. The Company
first publicly announced the appointment by press release on May 19, 2009, which
is attached as Exhibit 99.1 to this current report on Form 8-K.
Mr.
Mendell, 67, was a member of the Board of Directors of San Diego-based Gensia
Inc., a biotechnology company that later merged with Sicor Inc. to become Gensia
Sicor (and was later acquired by Teva Pharmaceuticals). He has also been a
member of the Board of Directors of the Biotechnology Industry Organization and
represented the biotechnology industry on the NASDAQ Corporate Advisory Board.
Mr. Mendell is also a former Inc. magazine Entrepreneur of the Year. He has a
bachelor’s degree from UC Santa Barbara and a graduate degree in international
management from The Thunderbird School of International Management.
Since
1999, Mr. Malchow, 55, has been President and Chief Executive Officer of Aliso
Viejo, CA-based SenoRx, Inc. (Nasdaq: SENO), which develops, manufactures and
markets minimally invasive devices for the diagnosis and treatment of breast
cancer. From 1993 to 1999, Mr. Malchow held various positions, including Chief
Operating Officer, President and Chief Executive Officer, at Foster City,
CA-based Penederm, a publicly traded drug delivery company acquired by
Pittsburgh, PA-based Mylan Laboratories in 1998. Mr. Malchow has also held
executive positions at Allergan and American Hospital Supply. At
Allergan he held several positions including Corporate Operating Committee
Member, Vice President of Sales, Ophthalmology Vice President and General
Manager of Skin Care. He currently serves on the Board of Directors of San
Clemente, CA-based Rox Medical, a privately-held medical device company that
develops products for the treatment of respiratory disease. Mr.
Malchow has a bachelor’s degree from Carroll College, a master’s degree from the
University of Maryland and an MBA from Pepperdine University.
Pursuant
to the Company’s non-employee director compensation policy, Messrs. Mendell
and Malchow each received 25,000 restricted stock units of the Company’s common
stock.
Item
9.01. Financial Statements and Exhibits.
(c)
Exhibits.
Exhibit
No.
|
|
Description
|
|
|
|
99.1
|
|
Text
of press release issued by Digirad Corporation, dated May 20,
2009.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
DIGIRAD
CORPORATION
|
|
|
|
|
By:
|
/s/
Todd Clyde
|
|
|
|
Todd
Clyde
Chief
Executive Officer
|
Date: May
19, 2009
Exhibit
Index
Exhibit
No.
|
|
Description
|
|
|
|
99.1
|
|
Text
of press release issued by Digirad Corporation, dated May 20,
2009.
|